Vaccinex Inc
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheime… Read more
Market Cap & Net Worth: Vaccinex Inc (VCNX)
Vaccinex Inc (NASDAQ:VCNX) has a market capitalization of $2.62 Million ($2.62 Million) as of March 19, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #35803 globally and #11657 in its home market, demonstrating a 71.93% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Vaccinex Inc's stock price $0.98 by its total outstanding shares 2676640 (2.68 Million).
Vaccinex Inc Market Cap History: 2018 to 2025
Vaccinex Inc's market capitalization history from 2018 to 2025. Data shows change from $2.05 Billion to $2.62 Million (-69.07% CAGR).
Vaccinex Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Vaccinex Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
43.71x
Vaccinex Inc's market cap is 43.71 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2018 | $2.05 Billion | $724.00K | -$29.52 Million | 2829.73x | N/A |
| 2019 | $2.73 Billion | $523.00K | -$32.02 Million | 5212.54x | N/A |
| 2020 | $1.16 Billion | $50.00K | -$29.31 Million | 23270.71x | N/A |
| 2021 | $584.58 Million | $900.00K | -$23.23 Million | 649.53x | N/A |
| 2022 | $362.27 Million | $100.00K | -$19.72 Million | 3622.70x | N/A |
| 2023 | $24.91 Million | $570.00K | -$20.25 Million | 43.71x | N/A |
Competitor Companies of VCNX by Market Capitalization
Companies near Vaccinex Inc in the global market cap rankings as of March 19, 2026.
Key companies related to Vaccinex Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Vaccinex Inc Historical Marketcap From 2018 to 2025
Between 2018 and today, Vaccinex Inc's market cap moved from $2.05 Billion to $ 2.62 Million, with a yearly change of -69.07%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $2.62 Million | -10.09% |
| 2024 | $2.92 Million | -88.29% |
| 2023 | $24.91 Million | -93.12% |
| 2022 | $362.27 Million | -38.03% |
| 2021 | $584.58 Million | -49.76% |
| 2020 | $1.16 Billion | -57.32% |
| 2019 | $2.73 Billion | +33.07% |
| 2018 | $2.05 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Vaccinex Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.62 Million USD |
| MoneyControl | $2.62 Million USD |
| MarketWatch | $2.62 Million USD |
| marketcap.company | $2.62 Million USD |
| Reuters | $2.62 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.